Cancer Doctor Tri-Cities

If you have recently been diagnosed with prostate cancer, you should know about the use of genomic testing of your prostate cancer tissue. The information derived from these tests (such as Prolaris, OncotypeDx, Decipher) assesses whether the tumor tissue has a genetic profile suggesting that it is more or less aggressive than the clinical risk group (low, intermediate or high-risk). This can be helpful for patients who are not certain if they want to pursue an active surveillance or a more aggressive management plan (prostatectomy or radiation therapy).